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Background
Gastric cancer at advanced stage of disease is a major
health problem and the prognosis with the current ther-
apeutic treatment strategies remains poor. PI3K/mTOR
pathway mutations, especially PTEN, PI3K3C and AKT
mutations and pS6 overexpression, are found frequently
in gastric cancer patients and are linked with poor out-
come. Thus, we evaluated the dual PI3K and mTOR
inhibitor BEZ235 against gastric cancer in vitro and
in vivo.
Materials and methods
Three gastric cancer cell lines (N87, MKN28 and
MKN45) were treated with BEZ235 (20–80 nM) and
assessed for cell viability, cell death and cell cycle distri-
bution. PI3K/mTOR proteint a r g e tm o d u l a t i o nw a s
measured by Western blotting. For in vivo studies athy-
mic nude mice were inoculated with N87 or MKN45
cells bilaterally and treated daily with 20 or 40 mg/kg
BEZ235. Tumor [
18F]fluorothymidine (FLT) uptake was
measured via small animal PET.
Results
In vitro, treatment of gastric cancer cells with 20–80 nM
BEZ235 decreased cell growth in a dose-dependent
manner in all cell lines tested (up to −70%). This anti-
proliferative activity was linked with a G1 cell cycle
arrest (up to 75%). No significant induction of apoptosis
by BEZ235 was observed. On the molecular level,
BEZ235 led to a decrease of phosphorylation of AKT
and S6 protein. In vivo, treatment with 20 and 40 mg/kg
BEZ235 resulted in a significant anti-tumor effect in a
N87 gastric cancer xenograft mouse model. BEZ235
therapy had no anti-tumort effect on MKN45 xenografts
despite similar potent PI3K/mTOR target inhibition by
BEZ235 in both xenograft models. However, expression
of the proliferation marker thymidinthymidine kinase
1 correlated with sensitivity to BEZ235 in vivo.I nl i n e ,
[
18F]FLT uptake was significantly reduced only in the
BEZ235-sensitive tumor xenograft model as measured
by small animal PET.
Conclusions
In conclusion, our study shows that dual PI3K/mTOR
inhibition by BEZ235 is a valuable target for gastric can-
cer therapy but is tumor model-dependent. Correlative
studies with implementation of non-invasive imaging
tools such as [
18F]FLT PET might be a novel and pro-
mising strategy for optimizing clinical testing of dual
PI3K/mTOR inhibitors.
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